Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Apr;14(4):397-403.
doi: 10.1128/CVI.00241-06. Epub 2007 Feb 7.

Avidity of the immunoglobulin G response to a Neisseria meningitidis group C polysaccharide conjugate vaccine as measured by inhibition and chaotropic enzyme-linked immunosorbent assays

Affiliations

Avidity of the immunoglobulin G response to a Neisseria meningitidis group C polysaccharide conjugate vaccine as measured by inhibition and chaotropic enzyme-linked immunosorbent assays

Shannon L Harris et al. Clin Vaccine Immunol. 2007 Apr.

Abstract

Antibody avidity, the strength of the multivalent interaction between antibodies and their antigens, is an important characteristic of protective immune responses. We have developed an inhibition enzyme-linked immunosorbent assay (ELISA) to measure antibody avidity for the capsular polysaccharide (PS) of Neisseria meningitidis group C (MnC) and determined the avidity constants (K(D)s) for 100 sera from children immunized with an MnC PS conjugate vaccine. The avidity constants were compared to the avidity indices (AI) obtained for the same sera using a chaotropic ELISA protocol. After the primary immunization series, the geometric mean (GM) K(D) was 674 nM and did not change in the months following immunization. However, the GM avidity did increase after the booster dose (GM K(D), 414 nM 1 month after booster immunization). In contrast, the GM AI increased from an initial value of 118 after the primary immunization series to 147 6 months after the completion of the primary immunization series and then further increased to 178 after booster immunization. At the individual subject level, the avidity constant and AI correlated after the primary immunization series and after booster immunization but not prior to boosting. This work suggests that the AI, as measured by the chaotropic ELISA, in contrast to the K(D), reflects changes that render antibody populations less susceptible to disruption by chaotropic agents without directly affecting the strength of the binding interactions.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Isotherm and nonlinear least-squares fit of data from isothermal titration microcalorimetry experiment with acetylated MnC PS and MAb MNC46-1, specific for deacetylated MnC PS. The average stoichiometry of binding (N), from three experiments with MAb 46-1 and two experiments with MAb MNC207-1, specific for acetylated MnC PS (data not shown), is 10.7 ± 1.5. K, thermodynamic binding constant; ΔH, enthalpy of binding; ΔS, entropy of binding.
FIG. 2.
FIG. 2.
Linearity of inhibition ELISA. After normalizing for antibody concentration, serum from adult 1, which had a high KD, was mixed with serum from adult 3, which had a low KD, to produce a mixed serum with a linear gradient of KDs. The obtained KDs are plotted against the percentage of serum from adult 1 for each mixed serum. The results of two independent experiments are shown. Experiment 1, black diamonds and solid line (R2 = 0.83). Experiment 2, open circles and dashed line (R2 = 0.95).
FIG. 3.
FIG. 3.
GM AI and GM KD for sera from children immunized with an MnC conjugate vaccine. Bars represent GM AI determined via chaotropic ELISA. Filled diamonds represent GM KD determined via inhibition ELISA for the same subjects. Error bars represent 95% confidence intervals for the geometric means. GM AI shows a significant increase at prebooster and postbooster time points, whereas GM KD shows a significant decrease (i.e., increased avidity) at the postbooster point only.
FIG. 4.
FIG. 4.
Correlation between KD and AI after primary-series immunization. At the post-primary-series time point, KD is 929.31 − 1.79 × AI (model F test: P = 0.0054 from the ANOVA table, with an R2 of 0.08). Data points are shown as squares and the regression function as a solid line. The dashed lines around the regression line represent the 95% confidence curves for the mean of KD.
FIG. 5.
FIG. 5.
Correlation between KD and AI before booster immunization. At the prebooster time point there is no linear relationship between KD and AI.
FIG. 6.
FIG. 6.
(a) Correlation between KD and AI post-booster immunization. At the postbooster time point, the regression model between KD and AI is a curve (model F test: P < 0.001 from the ANOVA table, with an R2 of 0.296). Data points are shown as squares and the regression function as a solid line. (b) Correlation between KD and AI after booster immunization. At the postbooster time point, KD_X is 167.53 − 56.59*log10(AI), where KD_X = (KD)0.6 and log10(AI) equals the log-transformed values of AI (model F test: P < 0.001 from the ANOVA table, with an R2 of 0.296). Data points are shown as squares and the regression function as a solid line. The dashed lines around the regression line represent the 95% confidence curves for the mean of KD.

Similar articles

Cited by

References

    1. Anttila, M., J. Eskola, H. Ahman, and H. Kayhty. 1998. Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines. J. Infect. Dis. 177:1614-1621. - PubMed
    1. Anttila, M., J. Eskola, H. Ahman, and H. Kayhty. 1999. Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhood. Vaccine 17:1970-1977. - PubMed
    1. Anttila, M., M. Voutilainen, V. Jantti, J. Eskola, and H. Kayhty. 1999. Contribution of serotype-specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniae. Clin. Exp. Immunol. 118:402-407. - PMC - PubMed
    1. Borrow, R., N. Andrews, D. Goldblatt, and E. Miller. 2001. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect. Immun. 69:1568-1573. - PMC - PubMed
    1. Borrow, R., D. Goldblatt, N. Andrews, P. Richmond, J. Southern, and E. Miller. 2001. Influence of prior meningococcal C polysaccharide vaccination on the response and generation of memory after meningococcal C conjugate vaccination in young children. J. Infect. Dis. 184:377-380. - PubMed

Publication types

MeSH terms

LinkOut - more resources